Risk Factors, Clinical Presentation, Diagnosis, and Treatment Outcomes of Portal Vein Thrombosis: A Five-Year Hospital-Based Study From Qatar
- PMID: 35720227
- PMCID: PMC9187352
- DOI: 10.14740/jocmr4718
Risk Factors, Clinical Presentation, Diagnosis, and Treatment Outcomes of Portal Vein Thrombosis: A Five-Year Hospital-Based Study From Qatar
Abstract
Background: There is a lack of robust epidemiological information on portal vein thrombosis (PVT) in Qatar. This study aimed to describe the risk factors, clinical presentation, diagnosis, and treatment outcomes of PVT in patients with and without liver cirrhosis admitted to Hamad General Hospital.
Methods: This retrospective observational study was conducted at Hamad General Hospital, Doha, Qatar. Consecutive patients with PVT between January 1, 2015 and December 31, 2019 were included in this study.
Results: We included 363 cases representing 0.05% of all inpatients admitted to our hospital during the study period. Their mean age was 47.79 ± 14.48 years. There were 258 (71.1%) males and 105 (28.9%) females. Abdominal pain was the most common presenting symptom (160 (44.1%)), while splenomegaly was the most common presenting sign (158 (43.5%)). Liver cirrhosis was the most frequent risk factor for PVT (147 (40.5%)), while no risk factors were identified in 49 (13.5%) patients. Anticoagulant therapy was given to 171/207 (82.6%) patients with acute PVT and 19/156 (12.2%) patients with chronic PVT. The options used for anticoagulation treatment were: low molecular weight heparin (LMWH) or unfractionated heparin alone, LMWH/unfractionated heparin followed by warfarin, and direct-acting oral anticoagulants (rivaroxaban). Out of the 262 patients in whom PVT recanalization was assessed, 43.8% of the cases had recanalization after anticoagulation treatment, while 12.6% of them had spontaneous recanalization without such therapy. A comparison between different anticoagulants used in this study showed no significant difference in the effectiveness of the three regimens used. The 30-day mortality was recorded for 71 patients (19.5%). The major risk factors for 30-day mortality were: age over 45 years, male sex, hepatic failure, malignancies, and bilirubin > 34 µmol/L.
Conclusion: PVT is a rare clinical entity in Qatar with liver cirrhosis being the most common risk factor. Early administration of anticoagulation therapy is associated with a significant recanalization, while age > 45 years, male sex, hepatic failure, malignancies, and bilirubin > 34 µmol/L are independent risk factors for 30-day mortality.
Keywords: Liver cirrhosis; Malignancy; Portal vein; Thrombophilia; Thrombosis.
Copyright 2022, Khan et al.
Conflict of interest statement
None to declare.
Similar articles
-
Anticoagulation in Cirrhosis and Portal Vein Thrombosis Is Safe and Improves Prognosis in Advanced Cirrhosis.Dig Dis Sci. 2019 Sep;64(9):2671-2683. doi: 10.1007/s10620-019-05572-z. Epub 2019 Mar 9. Dig Dis Sci. 2019. PMID: 30852769
-
Administration of anticoagulation strategies for portal vein thrombosis in cirrhosis: network meta-analysis.Front Pharmacol. 2025 Jan 6;15:1462338. doi: 10.3389/fphar.2024.1462338. eCollection 2024. Front Pharmacol. 2025. PMID: 39834816 Free PMC article.
-
Anticoagulation outcomes in cirrhotic patients with portal vein thrombosis: a tertiary center study.Postgrad Med J. 2025 Apr 29:qgaf062. doi: 10.1093/postmj/qgaf062. Online ahead of print. Postgrad Med J. 2025. PMID: 40298249
-
Anticoagulation and Transjugular Intrahepatic Portosystemic Shunt for the Management of Portal Vein Thrombosis in Cirrhosis: A Prospective Observational Study.Am J Gastroenterol. 2021 Jul 1;116(7):1447-1464. doi: 10.14309/ajg.0000000000001194. Am J Gastroenterol. 2021. PMID: 33630766
-
Management of portal vein thrombosis in liver cirrhosis.Nat Rev Gastroenterol Hepatol. 2014 Jul;11(7):435-46. doi: 10.1038/nrgastro.2014.36. Epub 2014 Apr 1. Nat Rev Gastroenterol Hepatol. 2014. PMID: 24686266 Review.
Cited by
-
Effect of Direct Oral Anticoagulants in Patients with Splanchnic Vein Thrombosis: A Systematic Reviews and Meta-Analysis.Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241274750. doi: 10.1177/10760296241274750. Clin Appl Thromb Hemost. 2024. PMID: 39135448 Free PMC article.
-
Factor V Leiden (R506Q), Prothrombin G20210A, and MTHFR C677T Variants and Thrombophilia in Qatar Biobank Participants: A Case Control Study.Pathophysiology. 2024 Oct 21;31(4):608-620. doi: 10.3390/pathophysiology31040044. Pathophysiology. 2024. PMID: 39449526 Free PMC article.
References
-
- Ogren M, Bergqvist D, Bjorck M, Acosta S, Eriksson H, Sternby NH. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol. 2006;12(13):2115–2119. doi: 10.3748/wjg.v12.i13.2115. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources